MX2024009974A - Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. - Google Patents

Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.

Info

Publication number
MX2024009974A
MX2024009974A MX2024009974A MX2024009974A MX2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A
Authority
MX
Mexico
Prior art keywords
cns
treatment
related disorders
neuroactive steroids
additional antidepressant
Prior art date
Application number
MX2024009974A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Jay Kanes
James Doherty
Handan Gunduz-Bruce
Robert Alfonso Lasser
Jeffrey Martin Jonas
Amy E Bullock
Timothy Y Mariano
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2024009974A publication Critical patent/MX2024009974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024009974A 2022-02-16 2023-02-15 Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. MX2024009974A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US202363482200P 2023-01-30 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (1)

Publication Number Publication Date
MX2024009974A true MX2024009974A (es) 2024-09-30

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009974A MX2024009974A (es) 2022-02-16 2023-02-15 Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.

Country Status (11)

Country Link
US (1) US20250295674A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508406A (cg-RX-API-DMAC7.html)
KR (1) KR20240148425A (cg-RX-API-DMAC7.html)
CN (1) CN119072304A (cg-RX-API-DMAC7.html)
AU (1) AU2023220976A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252357A1 (cg-RX-API-DMAC7.html)
IL (1) IL315023A (cg-RX-API-DMAC7.html)
MX (1) MX2024009974A (cg-RX-API-DMAC7.html)
TW (1) TW202341995A (cg-RX-API-DMAC7.html)
WO (1) WO2023158668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2023012727A (es) * 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Also Published As

Publication number Publication date
AU2023220976A1 (en) 2024-09-05
WO2023158668A1 (en) 2023-08-24
EP4479032A1 (en) 2024-12-25
JP2025508406A (ja) 2025-03-26
US20250295674A1 (en) 2025-09-25
TW202341995A (zh) 2023-11-01
CA3252357A1 (en) 2023-08-24
IL315023A (en) 2024-10-01
KR20240148425A (ko) 2024-10-11
CN119072304A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
MX2023007027A (es) Derivado de cannabinoide como compuesto farmaceuticamente activo y metodo de preparacion del mismo.
MX2023009610A (es) Esteroides neuroactivos, y su metodo de uso.
PY2036977A (es) Derivados de cannabinoides como compuestos farmacéuticamente activos y métodos de preparación de los mismos
MX2022013698A (es) Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina.
MX2023013250A (es) Derivado de resorcinol como compuesto farmaceuticamente activo y metodo de preparacion del mismo.
NZ751690A (en) Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
IL315023A (en) Neuroactive steroids for treatment of cns-related disorders
MX2023013247A (es) Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje.
MX2023012727A (es) Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
CO2023003533A2 (es) Métodos para el tratamiento de trastornos de mineralización ósea referencia cruzada a solicitudes relacionadas
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
CO2023016136A2 (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
MX2023005342A (es) Métodos para tratar padecimientos relacionados con el receptor s1p1.
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
BR112023018354A8 (pt) Métodos e usos de composições, componentes ou metabólitos de microbioma para tratar distúrbios oculares
BRPI0617382A2 (pt) Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
MX2022000356A (es) Compuesto para tratamiento de combinacion.
AR047716A1 (es) Combinaciones de analepticos y antidepresivos